Eosinophils as a predictive marker of treatment-related adverse events in mRCC patients treated with first-line immune-checkpoint inhibitor combination therapy
Abstract Immune checkpoint inhibitors (ICIs) are a key component of first-line treatment for metastatic renal cell carcinoma (mRCC). However, predicting treatment-related adverse events (TRAEs) remains challenging. This study investigated the utility of eosinophil-related biomarkers as predictors of...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-08767-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849763771975729152 |
|---|---|
| author | Tatsushi Kawada Satoshi Katayama Takafumi Yanagisawa Keiichiro Mori Wataru Fukuokaya Kazumasa Komura Takuya Tsujino Ryoichi Maenosono Kiyoshi Takahara Takuhisa Nukaya Lan Inoki Shingo Toyoda Takeshi Hashimoto Yosuke Hirasawa Kohei Edamura Tomoko Kobayashi Kensuke Bekku Shingo Nishimura Takehiro Iwata Takuya Sadahira Yusuke Tominaga Tomoaki Yamanoi Kasumi Yoshinaga Kazuma Tsuboi Yasuyuki Kobayashi Atsushi Takamoto Kyohei Kurose Takahiro Kimura Haruhito Azuma Ryoichi Shiroki Kazutoshi Fujita Yoshio Ohno Motoo Araki On behalf of JK-FOOT study group |
| author_facet | Tatsushi Kawada Satoshi Katayama Takafumi Yanagisawa Keiichiro Mori Wataru Fukuokaya Kazumasa Komura Takuya Tsujino Ryoichi Maenosono Kiyoshi Takahara Takuhisa Nukaya Lan Inoki Shingo Toyoda Takeshi Hashimoto Yosuke Hirasawa Kohei Edamura Tomoko Kobayashi Kensuke Bekku Shingo Nishimura Takehiro Iwata Takuya Sadahira Yusuke Tominaga Tomoaki Yamanoi Kasumi Yoshinaga Kazuma Tsuboi Yasuyuki Kobayashi Atsushi Takamoto Kyohei Kurose Takahiro Kimura Haruhito Azuma Ryoichi Shiroki Kazutoshi Fujita Yoshio Ohno Motoo Araki On behalf of JK-FOOT study group |
| author_sort | Tatsushi Kawada |
| collection | DOAJ |
| description | Abstract Immune checkpoint inhibitors (ICIs) are a key component of first-line treatment for metastatic renal cell carcinoma (mRCC). However, predicting treatment-related adverse events (TRAEs) remains challenging. This study investigated the utility of eosinophil-related biomarkers as predictors of Common Terminology Criteria for Adverse Events grade ≥ 3 TRAEs in mRCC patients undergoing ICI combination therapy. In this retrospective analysis across 21 hospitals in Japan, we examined 180 patients treated with ICI/ICI therapy and 216 patients treated with ICI/tyrosine kinase inhibitor (TKI) therapy. Grade ≥ 3 TRAEs occurred in 39.4% and 31.9% of patients in the ICI/ICI and ICI/TKI groups, respectively. An elevated eosinophil proportion of ≥ 2.0% (odds ratio [OR]: 2.36; 95% CI [confidence interval] 1.23–4.54, p = 0.01) and a low neutrophil/eosinophil ratio (NER) of ≤ 40.0 (OR: 2.78, 95% CI 1.39–5.53, p = 0.004) were significant predictors of severe TRAEs in the ICI/ICI group. However, no significant associations were found in the ICI/TKI group. These findings may help identify patients who suffer from grade ≥ 3 TRAEs and help determine individualized treatment strategies in patients with mRCC. |
| format | Article |
| id | doaj-art-e0091f8387b04643a4e5b552337ac88e |
| institution | DOAJ |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-e0091f8387b04643a4e5b552337ac88e2025-08-20T03:05:18ZengNature PortfolioScientific Reports2045-23222025-07-011511810.1038/s41598-025-08767-9Eosinophils as a predictive marker of treatment-related adverse events in mRCC patients treated with first-line immune-checkpoint inhibitor combination therapyTatsushi Kawada0Satoshi Katayama1Takafumi Yanagisawa2Keiichiro Mori3Wataru Fukuokaya4Kazumasa Komura5Takuya Tsujino6Ryoichi Maenosono7Kiyoshi Takahara8Takuhisa Nukaya9Lan Inoki10Shingo Toyoda11Takeshi Hashimoto12Yosuke Hirasawa13Kohei Edamura14Tomoko Kobayashi15Kensuke Bekku16Shingo Nishimura17Takehiro Iwata18Takuya Sadahira19Yusuke Tominaga20Tomoaki Yamanoi21Kasumi Yoshinaga22Kazuma Tsuboi23Yasuyuki Kobayashi24Atsushi Takamoto25Kyohei Kurose26Takahiro Kimura27Haruhito Azuma28Ryoichi Shiroki29Kazutoshi Fujita30Yoshio Ohno31Motoo Araki32On behalf of JK-FOOT study groupDepartment of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesDepartment of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesDepartment of Urology, The Jikei University School of MedicineDepartment of Urology, The Jikei University School of MedicineDepartment of Urology, The Jikei University School of MedicineDepartment of Urology, Osaka Medical and Pharmaceutical UniversityDepartment of Urology, Osaka Medical and Pharmaceutical UniversityDepartment of Urology, Osaka Medical and Pharmaceutical UniversityDepartment of Urology, Fujita Health University School of MedicineDepartment of Urology, Fujita Health University School of MedicineDepartment of Urology, Kindai University Faculty of MedicineDepartment of Urology, Kindai University Faculty of MedicineDepartment of Urology, Tokyo Medical UniversityDepartment of Urology, Tokyo Medical UniversityDepartment of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesDepartment of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesDepartment of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesDepartment of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesDepartment of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesDepartment of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesDepartment of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesDepartment of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesDepartment of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesDepartment of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesDepartment of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesDepartment of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesDepartment of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesDepartment of Urology, The Jikei University School of MedicineDepartment of Urology, Osaka Medical and Pharmaceutical UniversityDepartment of Urology, Fujita Health University School of MedicineDepartment of Urology, Kindai University Faculty of MedicineDepartment of Urology, Tokyo Medical UniversityDepartment of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesAbstract Immune checkpoint inhibitors (ICIs) are a key component of first-line treatment for metastatic renal cell carcinoma (mRCC). However, predicting treatment-related adverse events (TRAEs) remains challenging. This study investigated the utility of eosinophil-related biomarkers as predictors of Common Terminology Criteria for Adverse Events grade ≥ 3 TRAEs in mRCC patients undergoing ICI combination therapy. In this retrospective analysis across 21 hospitals in Japan, we examined 180 patients treated with ICI/ICI therapy and 216 patients treated with ICI/tyrosine kinase inhibitor (TKI) therapy. Grade ≥ 3 TRAEs occurred in 39.4% and 31.9% of patients in the ICI/ICI and ICI/TKI groups, respectively. An elevated eosinophil proportion of ≥ 2.0% (odds ratio [OR]: 2.36; 95% CI [confidence interval] 1.23–4.54, p = 0.01) and a low neutrophil/eosinophil ratio (NER) of ≤ 40.0 (OR: 2.78, 95% CI 1.39–5.53, p = 0.004) were significant predictors of severe TRAEs in the ICI/ICI group. However, no significant associations were found in the ICI/TKI group. These findings may help identify patients who suffer from grade ≥ 3 TRAEs and help determine individualized treatment strategies in patients with mRCC.https://doi.org/10.1038/s41598-025-08767-9Renal cell carcinomaImmune checkpoint inhibitorICIEosinophilImmune-related adverse eventTreatment-related adverse event |
| spellingShingle | Tatsushi Kawada Satoshi Katayama Takafumi Yanagisawa Keiichiro Mori Wataru Fukuokaya Kazumasa Komura Takuya Tsujino Ryoichi Maenosono Kiyoshi Takahara Takuhisa Nukaya Lan Inoki Shingo Toyoda Takeshi Hashimoto Yosuke Hirasawa Kohei Edamura Tomoko Kobayashi Kensuke Bekku Shingo Nishimura Takehiro Iwata Takuya Sadahira Yusuke Tominaga Tomoaki Yamanoi Kasumi Yoshinaga Kazuma Tsuboi Yasuyuki Kobayashi Atsushi Takamoto Kyohei Kurose Takahiro Kimura Haruhito Azuma Ryoichi Shiroki Kazutoshi Fujita Yoshio Ohno Motoo Araki On behalf of JK-FOOT study group Eosinophils as a predictive marker of treatment-related adverse events in mRCC patients treated with first-line immune-checkpoint inhibitor combination therapy Scientific Reports Renal cell carcinoma Immune checkpoint inhibitor ICI Eosinophil Immune-related adverse event Treatment-related adverse event |
| title | Eosinophils as a predictive marker of treatment-related adverse events in mRCC patients treated with first-line immune-checkpoint inhibitor combination therapy |
| title_full | Eosinophils as a predictive marker of treatment-related adverse events in mRCC patients treated with first-line immune-checkpoint inhibitor combination therapy |
| title_fullStr | Eosinophils as a predictive marker of treatment-related adverse events in mRCC patients treated with first-line immune-checkpoint inhibitor combination therapy |
| title_full_unstemmed | Eosinophils as a predictive marker of treatment-related adverse events in mRCC patients treated with first-line immune-checkpoint inhibitor combination therapy |
| title_short | Eosinophils as a predictive marker of treatment-related adverse events in mRCC patients treated with first-line immune-checkpoint inhibitor combination therapy |
| title_sort | eosinophils as a predictive marker of treatment related adverse events in mrcc patients treated with first line immune checkpoint inhibitor combination therapy |
| topic | Renal cell carcinoma Immune checkpoint inhibitor ICI Eosinophil Immune-related adverse event Treatment-related adverse event |
| url | https://doi.org/10.1038/s41598-025-08767-9 |
| work_keys_str_mv | AT tatsushikawada eosinophilsasapredictivemarkeroftreatmentrelatedadverseeventsinmrccpatientstreatedwithfirstlineimmunecheckpointinhibitorcombinationtherapy AT satoshikatayama eosinophilsasapredictivemarkeroftreatmentrelatedadverseeventsinmrccpatientstreatedwithfirstlineimmunecheckpointinhibitorcombinationtherapy AT takafumiyanagisawa eosinophilsasapredictivemarkeroftreatmentrelatedadverseeventsinmrccpatientstreatedwithfirstlineimmunecheckpointinhibitorcombinationtherapy AT keiichiromori eosinophilsasapredictivemarkeroftreatmentrelatedadverseeventsinmrccpatientstreatedwithfirstlineimmunecheckpointinhibitorcombinationtherapy AT watarufukuokaya eosinophilsasapredictivemarkeroftreatmentrelatedadverseeventsinmrccpatientstreatedwithfirstlineimmunecheckpointinhibitorcombinationtherapy AT kazumasakomura eosinophilsasapredictivemarkeroftreatmentrelatedadverseeventsinmrccpatientstreatedwithfirstlineimmunecheckpointinhibitorcombinationtherapy AT takuyatsujino eosinophilsasapredictivemarkeroftreatmentrelatedadverseeventsinmrccpatientstreatedwithfirstlineimmunecheckpointinhibitorcombinationtherapy AT ryoichimaenosono eosinophilsasapredictivemarkeroftreatmentrelatedadverseeventsinmrccpatientstreatedwithfirstlineimmunecheckpointinhibitorcombinationtherapy AT kiyoshitakahara eosinophilsasapredictivemarkeroftreatmentrelatedadverseeventsinmrccpatientstreatedwithfirstlineimmunecheckpointinhibitorcombinationtherapy AT takuhisanukaya eosinophilsasapredictivemarkeroftreatmentrelatedadverseeventsinmrccpatientstreatedwithfirstlineimmunecheckpointinhibitorcombinationtherapy AT laninoki eosinophilsasapredictivemarkeroftreatmentrelatedadverseeventsinmrccpatientstreatedwithfirstlineimmunecheckpointinhibitorcombinationtherapy AT shingotoyoda eosinophilsasapredictivemarkeroftreatmentrelatedadverseeventsinmrccpatientstreatedwithfirstlineimmunecheckpointinhibitorcombinationtherapy AT takeshihashimoto eosinophilsasapredictivemarkeroftreatmentrelatedadverseeventsinmrccpatientstreatedwithfirstlineimmunecheckpointinhibitorcombinationtherapy AT yosukehirasawa eosinophilsasapredictivemarkeroftreatmentrelatedadverseeventsinmrccpatientstreatedwithfirstlineimmunecheckpointinhibitorcombinationtherapy AT koheiedamura eosinophilsasapredictivemarkeroftreatmentrelatedadverseeventsinmrccpatientstreatedwithfirstlineimmunecheckpointinhibitorcombinationtherapy AT tomokokobayashi eosinophilsasapredictivemarkeroftreatmentrelatedadverseeventsinmrccpatientstreatedwithfirstlineimmunecheckpointinhibitorcombinationtherapy AT kensukebekku eosinophilsasapredictivemarkeroftreatmentrelatedadverseeventsinmrccpatientstreatedwithfirstlineimmunecheckpointinhibitorcombinationtherapy AT shingonishimura eosinophilsasapredictivemarkeroftreatmentrelatedadverseeventsinmrccpatientstreatedwithfirstlineimmunecheckpointinhibitorcombinationtherapy AT takehiroiwata eosinophilsasapredictivemarkeroftreatmentrelatedadverseeventsinmrccpatientstreatedwithfirstlineimmunecheckpointinhibitorcombinationtherapy AT takuyasadahira eosinophilsasapredictivemarkeroftreatmentrelatedadverseeventsinmrccpatientstreatedwithfirstlineimmunecheckpointinhibitorcombinationtherapy AT yusuketominaga eosinophilsasapredictivemarkeroftreatmentrelatedadverseeventsinmrccpatientstreatedwithfirstlineimmunecheckpointinhibitorcombinationtherapy AT tomoakiyamanoi eosinophilsasapredictivemarkeroftreatmentrelatedadverseeventsinmrccpatientstreatedwithfirstlineimmunecheckpointinhibitorcombinationtherapy AT kasumiyoshinaga eosinophilsasapredictivemarkeroftreatmentrelatedadverseeventsinmrccpatientstreatedwithfirstlineimmunecheckpointinhibitorcombinationtherapy AT kazumatsuboi eosinophilsasapredictivemarkeroftreatmentrelatedadverseeventsinmrccpatientstreatedwithfirstlineimmunecheckpointinhibitorcombinationtherapy AT yasuyukikobayashi eosinophilsasapredictivemarkeroftreatmentrelatedadverseeventsinmrccpatientstreatedwithfirstlineimmunecheckpointinhibitorcombinationtherapy AT atsushitakamoto eosinophilsasapredictivemarkeroftreatmentrelatedadverseeventsinmrccpatientstreatedwithfirstlineimmunecheckpointinhibitorcombinationtherapy AT kyoheikurose eosinophilsasapredictivemarkeroftreatmentrelatedadverseeventsinmrccpatientstreatedwithfirstlineimmunecheckpointinhibitorcombinationtherapy AT takahirokimura eosinophilsasapredictivemarkeroftreatmentrelatedadverseeventsinmrccpatientstreatedwithfirstlineimmunecheckpointinhibitorcombinationtherapy AT haruhitoazuma eosinophilsasapredictivemarkeroftreatmentrelatedadverseeventsinmrccpatientstreatedwithfirstlineimmunecheckpointinhibitorcombinationtherapy AT ryoichishiroki eosinophilsasapredictivemarkeroftreatmentrelatedadverseeventsinmrccpatientstreatedwithfirstlineimmunecheckpointinhibitorcombinationtherapy AT kazutoshifujita eosinophilsasapredictivemarkeroftreatmentrelatedadverseeventsinmrccpatientstreatedwithfirstlineimmunecheckpointinhibitorcombinationtherapy AT yoshioohno eosinophilsasapredictivemarkeroftreatmentrelatedadverseeventsinmrccpatientstreatedwithfirstlineimmunecheckpointinhibitorcombinationtherapy AT motooaraki eosinophilsasapredictivemarkeroftreatmentrelatedadverseeventsinmrccpatientstreatedwithfirstlineimmunecheckpointinhibitorcombinationtherapy AT onbehalfofjkfootstudygroup eosinophilsasapredictivemarkeroftreatmentrelatedadverseeventsinmrccpatientstreatedwithfirstlineimmunecheckpointinhibitorcombinationtherapy |